About Us ++ Who We Are
Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform.
About Us ++ Mission
We are a purpose-driven team, passionate about leveraging our PRODEGY platform to discover and develop targeted protein degraders to address severe unmet patient needs. In doing so, we seek to build Biotheryx into a leader in next-generation targeted protein degradation.